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Background: Long term serum urate (SU) lowering to a target of <0.36 mmol/l (6 mg/dl) is recommended for
effective gout management. However, many studies have reported low achievement of SU targets. The aim of this
cross-sectional study was to examine the clinical and psychological factors associated with SU targets in patients
with gout.
Methods: Patients with gout for <10 years were recruited from primary and secondary care settings. SU target was
defined as SU concentration <0.36 mmol/L at the time of the study visit. Both clinical and psychological factors
associated with SU target were analysed. The relationship between SU target and measures of gout activity such as
flare frequency, tophi, work absences, and Health Assessment Questionnaire-II was also analysed.
Results: Of the 273 patients enrolled into the study, 89 (32.6%) had SU concentration <0.36 mmol/L. Urate-
lowering therapy (ULT) use was strongly associated with SU target (p < 0.001). In those patients prescribed ULT
(n = 181), allopurinol dose, patient confidence to keep SU under control, female sex, and ethnicity were
independently associated with SU target. Other patient psychological measures and health-related behaviours,
including adherence scores, were not independently associated with SU target in those taking ULT. Creatinine
clearance, diuretic use, age, and body mass index were not associated with SU target. Patients at SU target
reported lower gout flare frequency, compared with those not at target (p = 0.03).
Conclusions: ULT prescription and dosing are key modifiable factors associated with achieving SU target. These
data support interventions focusing on improved use of ULT to optimise outcomes in patients with gout.
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Gout is characterised by deposition of monosodium
urate (MSU) crystals in the joints and other tissues. The
central strategy for management of gout is long term
serum urate (SU) lowering, which leads to dissolution of
MSU crystals, prevention of acute gout flares, and regres-
sion of tophi [1]. A number of studies have demonstrated
that long term SU lowering below a target of 0.36 mmol/l
(6 mg/dl) is required to achieve these outcomes [2-5].* Correspondence: n.dalbeth@auckland.ac.nz
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approach has been recommended in a number of gout
treatment guidelines [6,7]. However, studies from many
countries have shown that gout management is fre-
quently poor, with low achievement of treatment targets
[8-11]. A variety of factors may contribute to under-
treatment of gout [12]. Potential patient factors include
medical co-morbidities, concomitant medications, atti-
tudes to disease and therapy, and poor adherence to
urate-lowering therapy (ULT) [10,13,14]. Medical practi-
tioner factors may include prescription and adequate
dosing of ULT [8]. To date, these factors have not been
systematically explored in relation to achieving optimall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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guide treatment strategies to improve management of
gout. The aim of this study was to examine the clinical
and psychological factors associated with SU target
<0.36 mmol/L in patients with gout.Methods
Patients with gout for less than 10 years were recruited
by community advertising and through primary and
secondary care clinics in Auckland and Wellington,
New Zealand. As in other regions of the world, gout
management is frequently suboptimal in New Zealand
[8,15]. The inclusion criteria for this study were: a pre-
vious physician diagnosis of acute gout as defined by
the Wallace classification for acute gout [16]; first attack
of gout within the last 10 years; and ability to complete
forms in English and provide written informed consent.
Patients did not have an acute flare at the time of their
study visit. The New Zealand Multi Regional Ethics
Committee approved this study.
Participants attended a study visit which included a
comprehensive clinical assessment. The following data
were recorded: demographic data (age, gender, ethnicity),
gout history (confirmation of diagnosis, disease duration,
frequency of gout flares, gout treatments), medical
history, examination, questionnaires (including Health
Assessment Questionnaire (HAQ)-II, Brief Illness Per-
ception Questionnaire (B-IPQ) [17], confidence in gout
treatment questionnaire and a medication adherence
score related to ULT (completed only by those patients
taking ULT) [17]), and laboratory tests (including SU and
creatinine).
Patient self-reported confidence in gout treatment was
assessed using 0 (not at all confident)-10 (very
confident) Likert scales, which covered aspects of gout
management including confidence to follow recom-
mended diet, take ULT regularly, have blood tests and
keep blood urate level under control. These items were
adapted from a diabetes-specific Multidimensional Dia-
betes Questionnaire [18].
Data were analysed using SPSS (v19, SPSS Inc., Chicago,
IL). Means with standard deviations (SD) and percentages
were used to describe the clinical characteristics of par-
ticipants. SU target was defined as SU concentration
<0.36 mmol/L at the time of the study visit. T-tests and
Chi square analysis was used to compare the group of
patients at SU target with those who were not. Forward
stepwise logistic regression analysis was used to deter-
mine the independent variables associated with SU tar-
get in those prescribed ULT, with factors included in the
model with p < 0.15 in the univariate analysis. The mea-
sures of gout activity were pre-specified as flare frequency,
presence of tophi, work absences, and activity limitationas assessed by the HAQ-II. All tests were two tailed and
P< 0.05 was considered statistically significant.
Results
SU target and clinical characteristics
A total of 273 patients attended the study visit. There
were 89 (32.6%) patients with serum urate level
<0.36 mmol/L (‘at SU target’ group). The clinical charac-
teristics are shown for all patients in Table 1. Patients
were predominantly middle-aged men treated in primary
care. ULT was prescribed in 181 (66.3%) of the entire
group. Allopurinol was the most frequently used ULT, in
177 patients. Four patients received probenecid mono-
therapy, and no patients were taking febuxostat, benzbro-
marone or recombinant uricase. In univariate analysis, SU
target was associated with female sex, prescription of ULT,
and allopurinol dose (Table 1). No relationship was
observed between SU target and disease duration, body
mass index, diuretic use, serum creatinine, or creatinine
clearance. Anti-inflammatory treatments such as colchi-
cine or non-steroidal anti-inflammatory drugs were not
associated with SU targets, and rates of secondary care
management were not different between groups.
Psychological measures, health-related behaviours and
SU target
Although there was no difference between groups in
confidence to follow dietary advice, patients at SU target
reported greater confidence to take gout medications
regularly and to keep SU concentrations under control
(Table 2). The perceived ability of medications to control
gout (BIPQ treatment control score) and understanding
of disease (BIPQ understanding score) were higher in
those at SU target, compared with those not at target
(Table 2). Other illness perception scores and health-
related behaviours did not differ between the two groups
(Table 2 and data not shown). In univariate analysis of
those prescribed ULT, adherence scores were higher in
patients at SU target, compared to those who were not
at SU target (Table 2).
Clinical and psychological factors independently
associated with SU target
The factors independently associated with SU target
were determined using logistic regression analysis. All
factors with p < 0.15 in the univariate analysis were
included in the models. In those patients prescribed
ULT (n = 181), allopurinol dose, patient confidence to
keep SU under control, female sex, and ethnicity were
independently associated with SU target (Table 3).
Adherence scores, other self-efficacy measures and ill-
ness perception scores were not independently associated
with SU target.
Table 1 Clinical characteristics
At SU target (<0.36 mmol/L) Above SU target (≥0.36 mmol/L) p
n = 89 n=184
Age, years, mean (SD) 61 (14) 58 (16) 0.09
Male sex, n (%) 52 (58%) 143 (77.7%) 0.002
Māori or Pacific ethnicity, n (%) 15 (17%) 49 (26.6%) 0.09
Disease duration, years, mean (SD) 5.6 (4.8) 5.0 (3.0) 0.22
Treatment in secondary care, n (%) 16 (18%) 52 (28.2%) 0.07
Body mass index, kg/m2, mean (SD) 30.4 (6.8) 31.6 (6.5) 0.16
Diuretic use, n (%) 26 (29%) 54 (29.3%) 1.0
Any ULT, n (%) 74 (83%) 107 (58.1%) <0.001
Allopurinol use, n (%) 74 (83%) 103 (56.0%) <0.001
Allopurinol dose for patients on allopurinol, mg/day, mean (SD) 235 (87) 194 (98) 0.004
Probenecid use, n (%) 2 (2%) 6 (3.2%) 1.0
Colchicine use, n (%) 26 (31%) 61 (33.2%) 0.58
Non-steroidal anti-inflammatory use, n (%) 14 (16%) 43 (23.4%) 0.16
Serum urate, mmol/L, mean (SD) 0.27 (0.07) 0.47 (0.09) <0.001
Serum creatinine, μmol/l, mean (SD) 99 (77) 110 (62) 0.23
Creatinine clearance, ml/min, mean (SD) 68 (27) 70 (30) 0.51
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Patients at SU target reported lower gout flare frequency
(p = 0.03), compared with those who were not at target
(Table 4). There was a trend to less tophaceous disease
in the group at SU target (p = 0.08). There were no dif-
ferences between groups in HAQ-II scores or work
absences.
Discussion
Despite widespread recognition that long term SU low-
ering to target is required for good clinical outcomes in
gout, this study has confirmed that the majority of
patients with gout are not at SU target. This work has
highlighted ULT prescription and allopurinol dosing as
central modifiable factors associated with SU target. The
data emphasize the important role of the health careTable 2 Psychological measures, health-related behaviours an
At
n=
Confidence to keep serum urate under control, mean (SD)
Confidence to follow diet, mean (SD)
Confidence to have blood tests at recommended frequency, mean (SD)
Confidence to take gout medications regularly, mean (SD)
BIPQ treatment control score, mean (SD)
BIPQ personal control score, mean (SD)
BIPQ understanding score, mean (SD)
Adherence score (those on ULT only), mean (SD)
BIPQ: brief illness perception questionnaire.professional to ensure ULT prescription at sufficient
doses to reduce SU to target.
The finding that prescription and dose of allopurinol
are key variables associated with SU target is consistent
with previous reports from our group (in a different study
population of patients with longstanding gout) and from
others, showing a close relationship between allopurinol
doses and SU concentrations [8,9]. Collectively, these
findings provide further support for a treat-to-SU-target
approach to long term allopurinol dosing [19]. A recent
qualitative study of health care providers has identified
barriers to effective gout management which include lack
of knowledge about gout and reluctance to offer ULT as a
long-term management strategy [20]. Furthermore, a
‘package of care’ intervention with close monitoring by
nurse practitioners aimed to achieve serum urate targetd SU target
SU target (<0.36 mmol/L) Above SU target (≥0.36 mmol/L) p
89 n= 184
7.4 (2.4) 6.7 (2.7) 0.02
7.5 (2.3) 7.4 (2.3) 0.76
9.4 (1.1) 9.0 (2.0) 0.06
9.5 (1.4) 9.0 (1.7) 0.03
8.2 (2.4) 7.4 (2.8) 0.02
6.1 (3.1) 5.5 (3.1) 0.18
7.3 (2.6) 6.5 (2.8) 0.04
42.7 (2.7) 39.0 (7.4) <0.001
Table 3 Forward stepwise logistic regression analysis of factors associated with SU target in those taking ULT
Variable Odds ratio 95% CI p Model
Female sex 4.3 1.6-11.4 0.003 Adjusted R2 = 0.35, p < 0.001
Māori or Pacific ethnicity 0.19 0.07-0.52 0.001
Allopurinol dose (per every 100 mg/day) 2.22 1.43-3.44 <0.001
Confidence to keep serum urate under control
(per every point on 0–10 Likert scale)
1.025 1.007-1.044 0.006
Excluded from model: secondary care treatment, adherence score, age, confidence to have blood tests at recommended frequency, confidence to take gout
medications regularly, BIPQ treatment control score, BIPQ understanding score.
Model included all factors with p < 0.15 between groups in univariate analysis.
Dalbeth et al. BMC Musculoskeletal Disorders 2012, 13:174 Page 4 of 5
http://www.biomedcentral.com/1471-2474/13/174has shown excellent results in patients with gout [21].
Our data further highlight the need for education of
health care professionals and changes in prescriber be-
haviour to optimize gout management.
Many recent studies and commentaries have focused
on the need to address patient factors such as adherence
and health related behaviours for optimal treatment of
gout [10,22-24]. However, in our analysis of patients tak-
ing ULT, adherence was not an independent variable in
the logistic regression model which included allopurinol
dose. Furthermore, aside from confidence to keep SU
under control, patient psychological factors and health-
related behaviours were not independently associated
with SU target in those taking ULT. These data do not
discount the potential role of patient behaviours, but
highlight the dominant role of effective ULT prescribing.
The cross-sectional design of this study does not allow
conclusions to be made about the direction of the rela-
tionship between SU target and confidence to keep SU
under control; that is, whether high confidence to keep
SU under control reflects the patient’s experience of
good control, or influences the ability to achieve target.
It is possible that feedback from clinic visits in patients
achieving SU target increases confidence and reinforces
behaviour. Longitudinal analysis of this group is under-
way to further address this issue.
This study has also identified several independent
non-modifiable variables associated with SU target.
Women were more likely to be at target. It is possible
that allopurinol doses relative to creatinine clearance
may have been higher in women. However, we did not
observe a relationship between creatinine clearance and
SU targets in this study. Patients of Māori or PacificTable 4 Serum urate target and measures of gout activity
At SU target (<0.36 mm
n=89
Flare frequency, mean (SD) 1.2 (2.3)
Presence of tophi, n (%) 9 (10%)
HAQ-II, mean (SD) 0.46 (0.52)
Days off work due to gout, mean (SD) 1.2 (5.6)ethnicity were less likely to be at target. Population
based studies have demonstrated that men and those of
Polynesian ancestry have higher mean SU concentrations
[25,26], and high baseline levels may mean that thera-
peutic SU targets are more difficult to achieve. Alterna-
tively, different health-care utilisation behaviour between
different sexes or ethnicities may have contributed to
the differences observed. Of interest, other clinical vari-
ables associated with higher SU concentrations such as
diuretic use, body mass index and creatinine clearance
were not associated with SU target.
We acknowledge the potential limitations of this study.
Long-term SU lowering is recommended for optimal
gout management, and this study has addressed SU
target at a single timepoint. Furthermore, the cross-
sectional nature of this study does not allow analysis of
the direction of the relationship between SU target and
other variables. However, many of the variables included
in the analysis are modifiable and dynamic, and this
approach allowed for direct analysis of these variables at
the time that the SU was obtained. Although patients
were recruited from a wide range of clinical settings, ad-
herence and health-related behaviours may be different
in those willing to participate in a research study, com-
pared with those who are not. The study design is not
able to capture an individual physician’s reasons for not
escalating doses of ULT, emphasizing the importance of
future studies examining why physicians do not initiate
ULT or titrate appropriately. Consistent with other
studies in gout, flare frequency was self-reported, and
not verified by a health care professional. However, this
definition is consistent with that used in other long
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In summary, SU target is frequently not achieved in
patients with gout. Greater ULT use and higher doses of
allopurinol, rather than patient behaviours, are the key
modifiable variables associated with suppression of SU
to target. These data support interventions focusing on
prescription and dosing of ULT to improve outcomes in
patients with gout.
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